Shareholder Information
2017, an extraordinary year by any measure
Dear Shareholders,
The official change of our company name from Galenica Ltd. to Vifor Pharma Ltd. was approved at the 89th Annual General Meeting on 11 May 2017. Our new name constitutes another major step on our journey toward becoming a pure-play pharmaceutical company and improving the lives of patients through global leadership in iron deficiency, nephrology and cardio-renal therapies.
The decision to sell off our historical core business, Galenica Santé, through a highly successful IPO (largest healthcare IPO in 2017) was taken to maximise Vifor Pharma’s growth potential and to build on our proud heritage of creating value for shareholders over many decades.
With our ‘Milestone 2020’ plan we entered a new phase in the extraordinary life of our company. ‘Milestone 2020’ will give us a strategic, very strong position as a global pharmaceutical company. Together with our already attractive portfolio of products either on the market or ready for launch and the fact that we are in a cash-positive net of debt situation of CHF 191.1m as at 31 December 2017, we have the foundation for long-term success.
By investing in our company now, we are fully leveraging the potential of Vifor Pharma Group.
We are fortunate and grateful that you, our shareholders, have supported us time and time again in making our vision reality and in helping us to be the best we can possibly be.
Sincerely,
Etienne Jornod
Executive Chairman
Links